These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 24627522)

  • 1. Does rFVIIa work solo in hemophilia?
    Margaritis P
    Blood; 2014 Mar; 123(11):1631-3. PubMed ID: 24627522
    [No Abstract]   [Full Text] [Related]  

  • 2. FVIIa as used pharmacologically is not TF dependent in hemophilia B mice.
    Feng D; Whinna H; Monroe D; Stafford DW
    Blood; 2014 Mar; 123(11):1764-6. PubMed ID: 24425804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model.
    Hoffman M; Chang JY; Ezban M; Monroe DM
    J Thromb Haemost; 2016 Jun; 14(6):1249-54. PubMed ID: 26952654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.
    Morfini M
    Eur J Haematol; 2016 Feb; 96(2):111-8. PubMed ID: 26172449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant factor VIIa in trauma patients without coagulation disorders.
    Scher C; Narine V; Chien D
    Anesthesiol Clin; 2010 Dec; 28(4):681-90. PubMed ID: 21074745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors.
    Milošević D; Bilić E; Batinić D; Poropat M; Štern-Padovan R; Galić S; Turudić D
    BMC Pediatr; 2014 Dec; 14():315. PubMed ID: 25515020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
    Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
    Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of coagulation activation in humans.
    Bauer KA; Eichinger S; Mannucci PM; Rosenberg RD
    Haemostasis; 1996; 26 Suppl 1():72-5. PubMed ID: 8904177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U; Lee CA
    Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arthroscopic synovectomy of the elbow covered with rFVIIa in a haemophilia B juvenile with inhibitor.
    Shimada K; Takedani H; Inoue K; Yamasaki K
    Haemophilia; 2012 Nov; 18(6):e414-6. PubMed ID: 22888990
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of preparation PPSB on coagulation and hemostasis in hemophilia B patients].
    Tarasova LN; Sadkov SA; Porokhnenko SG
    Gematol Transfuziol; 1984 Aug; 29(8):22-4. PubMed ID: 6479558
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent.
    Hedner U; Brun NC
    Neuroradiology; 2007 Oct; 49(10):789-93. PubMed ID: 17653706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor VIIa: its background, development and clinical use.
    Hedner U
    Curr Opin Hematol; 2007 May; 14(3):225-9. PubMed ID: 17414211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors.
    Chuansumrit A; Sri-Udomporn N; Srimuninnimit V; Juntarukha R
    Haemophilia; 2001 Sep; 7(5):532-4. PubMed ID: 11554948
    [No Abstract]   [Full Text] [Related]  

  • 20. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
    Valentino LA; Cooper DL; Goldstein B
    Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.